INSM · Company research
Insmed, Inc. (INSM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| INSM Oct 2026 90.000 put (INSM261016P00090000) Stock Price, News, Quote & History - Yahoo! Finance Canada | INSM Oct 2026 90.000 put (INSM261016P00090000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Three trials have started for Insmed's inhaled treatment; a fourth is expected in the first half of 2027. - Stock Titan | Three trials have started for Insmed's inhaled treatment; a fourth is expected in the first half of 2027. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| INSM Oct 2026 95.000 put (INSM261016P00095000) Stock Price, News, Quote & History - Yahoo! Finance Canada | INSM Oct 2026 95.000 put (INSM261016P00095000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Insmed (INSM) Stock Overview - Simply Wall Street | Insmed (INSM) Stock Overview Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| Insmed (INSM) Stock Looks About Right Following Raised 2026 Revenue Guidance - Simply Wall Street | Insmed (INSM) Stock Looks About Right Following Raised 2026 Revenue Guidance Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| Three presentations will examine an inhaled treatment being studied for high blood pressure in the lungs. - Stock Titan | Three presentations will examine an inhaled treatment being studied for high blood pressure in the lungs. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance UK | Insmed Incorporated (INSM) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits | INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada | Insmed Incorporated (INSM) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative? - Yahoo Finance | Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| INSM Stock Slides on CFO Exit, Reiterates '26 Sales View | Insmed's stock fell nearly 7% following the announcement that CFO Sara Bonstein will step down effective October 30 after nearly seven years in the role. Despite the leadership transition, the company reaffirmed its 2026 revenue guidance, expecting Brinsupri revenues of $1.25-$1.40 billion and Arikayce sales of $450-$470 million. The decline reflects investor uncertainty about the unexpected departure of a key executive during a critical growth phase. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bearish | -1 | 1 |
| INSM Stock Slides on CFO Exit, Reiterates '26 Sales View | Insmed's stock fell nearly 7% following the announcement that CFO Sara Bonstein will step down effective October 30 after nearly seven years in the role. Despite the leadership transition, the company reaffirmed its 2026 revenue guidance, expecting Brinsupri revenues of $1.25-$1.40 billion and Arikayce sales of $450-$470 million. The decline reflects investor uncertainty about the unexpected departure of a key executive during a critical growth phase. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bearish | -1 | 1 |
| INSM Stock Slides on CFO Exit, Reiterates '26 Sales View - TradingView | INSM Stock Slides on CFO Exit, Reiterates '26 Sales View TradingView | View source ↗ | TradingView | Oct 6, 2026 | neutral | 0 | 0.6 |
| Insmed CFO Transition Amid Reaffirmed 2026 Revenue Outlook - The Globe and Mail | Insmed CFO Transition Amid Reaffirmed 2026 Revenue Outlook The Globe and Mail | View source ↗ | The Globe and Mail | Oct 6, 2026 | neutral | 0 | 0.6 |
| $INSM stock is down 9% today. Here's what we see in our data. - Quiver Quantitative | $INSM stock is down 9% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 5, 2026 | neutral | 0 | 0.6 |
| Insmed drops as investors weigh CFO departure despite reaffirmed 2026 outlook - Quiver Quantitative | Insmed drops as investors weigh CFO departure despite reaffirmed 2026 outlook Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 5, 2026 | neutral | 0 | 0.6 |
| After nearly seven years, Insmed’s CFO will step down Oct. 30. - Stock Titan | After nearly seven years, Insmed’s CFO will step down Oct. 30. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us | Insmed Stock Price Forecast. Should You Buy INSM? StockInvest.us | View source ↗ | StockInvest.us | Oct 2, 2026 | neutral | 0 | 0.6 |
| Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance UK | Insmed Incorporated (INSM) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 2, 2026 | neutral | 0 | 0.6 |
| Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback | A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback | A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Why Insmed (INSM) Stock Is Down Today - Quiver Quantitative | Why Insmed (INSM) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.